Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes

Summary

Gut Dysbiosis had been involved in some way in the pathogenesis of some extra-intestinal disorders including metabolic syndrome, cardiovascular disease, and obesity.

Timeline

Start

2018-11-01

Primary completion

2019-06

Completion

2019-07-01

Drugs

Indications